181144-66-1

Basic information

• Product Name: Co102862
• Synonyms: Co102862;2-[[4-(4-Fluorophenoxy)phenyl]methylene]hydrazinecarboxamide;(E)-2-(4-(4-fluorophenoxy)benz-ylidene)hydrazinecarboxaMide;[(E)-[4-(4-fluorophenoxy)phenyl]methyleneamino]urea
• CAS NO: 181144-66-1
• Molecular Formula: C14H12FN3O2
• Molecular Weight: 273.266
• Mol File: 181144-66-1.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.278g/cm³
• Refractive Index: 1.589
• Storage Temp.: Store at RT
• CAS DataBase Reference: Co102862(CAS DataBase Reference)
• NIST Chemistry Reference: Co102862(181144-66-1)
• EPA Substance Registry System: Co102862(181144-66-1)

Safety Data

• Hazardous Substances Data: 181144-66-1(Hazardous Substances Data)

Usage

Biological Activity

Broad spectrum, state-dependent blocker of voltage-gated sodium channels. Displays ~ 80-fold higher affinity for inactivated Na + channels compared to channels in the resting state. Anticonvulsant; displays activity in rodent models of tonic/clonic and partial-complex seizures.

InChI:InChI=1/C14H12FN3O2/c15-11-3-7-13(8-4-11)20-12-5-1-10(2-6-12)9-17-18-14(16)19/h1-9H,(H3,16,18,19)/b17-9+

Upstream product

• 563-41-7 semicarbazide hydrochloride 
• 137736-06-2 4-(4-fluorophenoxy)benzaldehyde 
• 371-41-5 4-Fluorophenol 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 215458-98-3 4-(4-Fluorophenoxy)benzaldehyde 2'-(carbamylmethyl)semicarbazone 

Relevant articles and documents

(Aryloxy)aryl semicarbazones and related compounds: A novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen

A number of (aryloxy)aryl semicarbazones and related compounds were synthesized and evaluated far anticonvulsant activities. After intraperitoneal injection to mice, the semicarbazones were examined in the maximal electroshock (MES), subcutaneous pentylenetetrazole (scPTZ), and neurotoxicity (NT) screens. The results indicated that greater protection was obtained in the MES test than the scPTZ screen. Quantitation of approximately one-third of the compounds revealed an average protection index (PI, i.e. TD50/ED50) of approximately 9. After oral administration to rats, a number of compounds displayed significant potencies in the MES screen (ED50 of 1-5 mg/kg) accompanied by very high protection indices. In fact over half the compounds had PI figures of greater than 100, and two were in excess of 300. The compounds were essentially inactive in the scPTZ and NT screens after oral administration to rats. Various compounds displayed greater potencies and PI figures in the mouse intraperitoneal and rat oral screens than three reference clinically used drugs. The data generated supported a binding site hypothesis. Quantitative structure-activity relationships indicated a number of physicochemical parameters which contributed to activity in the MES screen. X-ray crystallography of five compounds suggested the importance of certain interatomic distances and bond angles for activity in the mouse and rat MES screens.